<DOC>
	<DOCNO>NCT01360437</DOCNO>
	<brief_summary>This single-center , randomize , single-blind , investigator-initiated pharmacological study crossover design . Patients acute coronary syndrome ( ST-elevation myocardial infarction , non-ST elevation myocardial infarction , unstable angina ) present high on-clopidogrel platelet reactivity assess VerifyNow assay ( platelet reactivity unit PRU≥235 ) 24 hour post percutaneous coronary intervention ( PCI ) , randomize informed consent 1:1 ratio either prasugrel 10mg/d ticagrelor 90mg twice day 15 day . Platelet reactivity assessment perform Day 15±2 day crossover directly alternate treatment group additional 15 day period , without intervene washout period carry . Patients return Day 30±2 day platelet reactivity assessment .</brief_summary>
	<brief_title>Ticagrelor Versus Prasugrel Acute Coronary Syndromes After Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Patients PCI stenting 24 hour prior randomization , meet one follow criterion : Acute coronary syndrome ( unstable angina myocardial infarction ) TIMI risk score &gt; 2 3 . Platelet reactivity PRU ≥235 24 hour postPCI 4 . Informed consent obtain write Treatment investigational agent ( include placebo ) device within 30 day prior randomization plan use investigational agent device prior Day 30 visit . Pregnancy Breastfeeding Inability give inform consent high likelihood unavailable Day 30 follow . Prior PCI perform within 30 day prior randomization Cardiogenic shock Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( pseudoaneurysm , arteriovenous shunt , retroperitoneal bleed hematoma &gt; 5 cm arterial catheter insertion site ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) . Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) plan stag PCI next 30 day randomization Requirement oral anticoagulant prior Day 30 visit Current plan therapy thienopyridine class ADP receptor inhibitor . Known hypersensitivity prasugrel ticagrelor History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . Other bleed diathesis , consider investigator high risk bleed longterm thienopyridine therapy . Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thombocytopenia ( &lt; 100.000 / μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Severe allergy contrast agent , unfractionated heparin , enoxaparin bivalirudin adequately premedicated . Recent ( &lt; 6 week ) major surgery trauma , include GABG . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>coronary angioplasty</keyword>
	<keyword>clopidogrel hyporesponsiveness</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>CAD</keyword>
	<keyword>ACS</keyword>
</DOC>